Semaglutide: A Promising Ally Against Alzheimer’s?

In a groundbreaking study, researchers at Case Western Reserve School of Medicine have identified a potential new benefit of semaglutide, a widely used diabetes and weight-loss drug. According to their findings, semaglutide may significantly reduce the risk of Alzheimer’s disease in individuals with type 2 diabetes (T2D), outperforming seven other anti-diabetic medications.

Alzheimer’s disease, a devastating brain disorder that erodes memory and cognitive abilities, affects nearly 7 million Americans aged 65 and older, as reported by the Alzheimer’s Association. Alarmingly, it claims more lives annually than breast and prostate cancer combined.

Published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, the study suggests that T2D patients taking semaglutide had a markedly lower risk of developing Alzheimer’s disease. This trend was consistent across various subgroups, regardless of obesity status, gender, or age.

Semaglutide, a glucagon-like peptide receptor (GLP-1R) agonist, is the active ingredient in popular medications like Wegovy and Ozempic. It works by reducing hunger and regulating blood sugar levels in T2D patients.

Rong xu

Under the leadership of Rong Xu, a professor of biomedical informatics, the research team analyzed three years of electronic health records from nearly one million U.S. patients with T2D. Their statistical approach, which mimicked a randomized clinical trial, revealed that patients prescribed semaglutide had a significantly lower risk of Alzheimer’s compared to those on other anti-diabetic medications.

According to the CDC, Alzheimer’s disease results in approximately 120,000 deaths annually, ranking as the seventh-leading cause of death in the United States.

“This new study provides real-world evidence for semaglutide’s potential impact on Alzheimer’s disease,” Xu stated. “While preclinical research has hinted at its protective effects against neurodegeneration and neuroinflammation, our findings suggest the need for further exploration through randomized clinical trials.”

Despite these promising results, the study’s limitations prevent researchers from drawing definitive causal conclusions. Xu emphasized the importance of continued research into semaglutide’s potential as a treatment for this debilitating condition, encouraging further investigation into alternative drugs.

For more information, please contact Patty Zamora at [email protected].

More Articles

Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!

Global Capital Is Reshaping Real Estate for 2026

Investors worldwide are redeploying capital, embracing more active deal structures, and expanding into new regions as the 2026 market takes shape. Data centers, revived office demand, and global diversification are driving a major shift—creating fresh opportunities for real estate, mortgage, and finance professionals who understand where capital is heading next.

Florida’s Home Insurance Crisis Hits Breaking Point as Premiums Soar and Claims Go Unpaid

Florida homeowners now pay an average of $5,838 per year for insurance—about $3,000 more than the national average—pushing many families to the financial brink. Residents report premiums tripling, claims being severely underpaid, and insurers dropping policies at one of the highest rates in the country. As frustration mounts, lawmakers and industry experts are calling for sweeping reforms to curb rising costs, increase accountability, and stabilize a market that’s reshaping real estate decisions across the state.

Citizens Insurance Steps Back as Florida’s Private Market Surges

Florida’s insurance market has hit a major turning point. Citizens Property Insurance—once the state’s largest insurer with 1.4 million policies—has shed more than 900,000 policies as private insurers return in force. Driven by Florida’s depopulation program and the arrival of 17 new companies, nearly 200,000 policies shifted to private carriers in October alone, with about 40 percent offering lower premiums. The shift signals rising competition, stabilizing rates, and new opportunities for homeowners and industry professionals navigating Florida’s evolving insurance landscape.

NAR Unveils Biggest MLS Policy Overhaul in 20 Years, Effective 2026

The National Association of REALTORS® has approved 18 major updates to modernize its MLS policies—the largest overhaul in two decades. Announced at NAR NXT in Houston and set to take effect in January 2026, the changes aim to streamline MLS operations, improve enforcement clarity, and better align policies with how today’s real estate professionals actually work.

Inhabit Unveils New AI and Fraud Prevention Tools Transforming Property Management

Inhabit has rolled out a powerful lineup of AI-driven leasing, marketing, fraud prevention, and compliance tools designed to streamline operations and protect property teams from growing risks. From hybrid AI leasing assistants to instant income verification and upcoming portfolio-wide lease audits, these innovations aim to cut costs, eliminate inefficiencies, and strengthen regulatory confidence across the multifamily industry.

Florida’s Insurance System Is Shifting Again—But Are Homeowners Still in the Danger Zone?

Florida’s latest round of insurance reforms was meant to calm a volatile market, yet many experts warn the same deep structural problems remain. Homeowners are being pushed from Citizens into higher‑priced, lightly capitalized private insurers, ratings agencies face scrutiny for inflated grades, and political influence clouds oversight. For real estate and insurance professionals, these trends signal ongoing risk, rising costs, and a market in need of a complete rebuild.